BPMC Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 4.21%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $31,955,826.64

Blueprint Medicines Insider Trading History Chart

Blueprint Medicines Share Price & Price History

^$84.10

▼ -2.46 (-2.84%)

As of 09/12/2024 01:00 AM ET

Days: 30 | 90 | 365

The $15 "Insider Secret" That Could Save Your Retirement

From Behind the Markets | Ad

What if I told you there's a $15 stock that a billionaire insider just poured $47 MILLION into? That's right. You can grab shares of this potential retirement-maker for less than you'd pay for lunch.

Click here to discover the name and ticker of this "$15 billionaire-backed retirement stock" >>>

Blueprint Medicines Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/5/2024	Philina Lee	Insider	Sell	41,913	$93.19	$3,905,872.47	34,729
7/5/2024	Debra Durso-Bumpus	Insider	Sell	3,850	$111.20	$428,120.00	43,763
7/3/2024	Debra Durso-Bumpus	Insider	Sell	8,817	$111.29	$981,243.93	43,763
6/28/2024	Debra Durso-Bumpus	Insider	Sell	333	$111.15	$37,012.95	43,763
6/21/2024	Debra Durso-Bumpus	Insider	Sell	74,034	$104.19	$7,713,602.46	43,763
6/5/2024	Percy H. Carter	Insider	Sell	4,000	$105.13	$420,520.00	41,895
6/3/2024	L. Becker Hewes	Insider	Sell	4,922	$106.43	$523,848.46	31,938
5/31/2024	L. Becker Hewes	Insider	Sell	34,108	$105.91	$3,612,378.28	36,860
5/2/2024	Ariel Hurley	Insider	Sell	1,834	$103.88	$190,515.92	14,913
5/2/2024	Michael Landsittel	CFO	Sell	10,000	$105.00	$1,050,000.00	47,286
3/28/2024	Michael Landsittel	CFO	Sell	5,000	$95.00	$475,000.00	47,286
3/20/2024	Jeffrey W. Albers	Director	Sell	25,073	$87.28	$2,188,371.44	176,050
3/15/2024	Michael Landsittel	CFO	Sell	13,734	$87.78	$1,205,570.52	47,286
3/7/2024	Christina Rossi	COO	Sell	6,070	$90.69	$550,488.30	64,306
3/7/2024	Jeffrey W. Albers	Director	Sell	11,033	$90.69	$1,000,582.77	165,017
3/7/2024	Kate Haviland	CEO	Sell	12,464	$90.69	$1,130,360.16	153,177
3/7/2024	L. Becker Hewes	Insider	Sell	3,097	$90.69	$280,866.93	46,281
3/7/2024	Michael Landsittel	CFO	Sell	5,003	$90.69	$453,722.07	56,020
3/7/2024	Tracey L. Mccain	EVP	Sell	5,194	$90.69	$471,043.86	60,498
3/4/2024	Christopher K. Murray	Insider	Sell	621	$93.65	$58,156.65	36,374
2/28/2024	Christopher K. Murray	Insider	Sell	5,000	$100.00	$500,000.00	24,495
1/25/2024	Jeffrey W. Albers	Director	Sell	25,000	$81.91	$2,047,750.00	176,050
12/22/2023	Ariel Hurley	Insider	Sell	714	$90.00	$64,260.00	14,324
12/7/2023	Christopher K. Murray	Insider	Sell	5,000	$75.00	$375,000.00	24,495
12/4/2023	Christopher K. Murray	Insider	Sell	600	$71.43	$42,858.00	24,495
11/30/2023	Jeffrey W. Albers	Director	Sell	5,000	$70.55	$352,750.00	176,050
11/24/2023	Jeffrey W. Albers	Director	Sell	15,000	$67.51	$1,012,650.00	176,050
11/3/2023	Jeffrey W. Albers	Director	Sell	1,485	$60.13	$89,293.05	176,050
11/1/2023	Jeffrey W. Albers	Director	Sell	3,881	$60.02	$232,937.62	176,050
10/26/2023	Christopher K. Murray	Insider	Sell	600	$56.40	$33,840.00	25,095
10/4/2023	Fouad Namouni	Insider	Sell	3,769	$48.06	$181,138.14	62,080
9/28/2023	Jeffrey W. Albers	Director	Sell	6,898	$50.17	$346,072.66	176,050
8/25/2023	Jeffrey W. Albers	Director	Sell	10,000	$50.16	$501,600.00	176,050
6/5/2023	Percy H. Carter	Insider	Sell	2,307	$52.06	$120,102.42	38,117
3/6/2023	Christina Rossi	COO	Sell	3,059	$45.67	$139,704.53	55,376
3/6/2023	Christopher K. Murray	Insider	Sell	1,875	$45.68	$85,650.00	25,695
3/6/2023	Jeffrey W. Albers	Director	Sell	9,793	$45.67	$447,246.31	173,450
3/6/2023	Kate Haviland	CEO	Sell	6,640	$45.69	$303,381.60	125,641
3/6/2023	Michael Landsittel	CFO	Sell	3,007	$45.68	$137,359.76	48,523
3/6/2023	Tracey L. Mccain	EVP	Sell	3,322	$45.68	$151,748.96	52,666
12/5/2022	Jeffrey W. Albers	Director	Sell	20,000	$50.09	$1,001,800.00	183,243
11/3/2022	Christina Rossi	COO	Sell	533	$45.24	$24,112.92	43,435
11/3/2022	Kate Haviland	CEO	Buy	1,100	$43.98	$48,378.00	92,281
10/4/2022	Fouad Namouni	Insider	Sell	3,477	$67.30	$234,002.10	52,797
8/24/2022	Debra Durso-Bumpus	Insider	Sell	5,000	$75.11	$375,550.00	40,836
8/22/2022	Jeffrey W. Albers	Director	Sell	8,410	$70.54	$593,241.40	183,243
8/19/2022	Jeffrey W. Albers	Director	Sell	1,590	$70.02	$111,331.80	183,243
8/16/2022	Jeffrey W. Albers	Director	Sell	20,000	$68.41	$1,368,200.00	183,243
8/8/2022	Jeffrey W. Albers	Director	Sell	10,000	$70.07	$700,700.00	183,243
8/4/2022	Christopher K. Murray	SVP	Sell	2,500	$60.44	$151,100.00	21,320
6/6/2022	Percy H. Carter	Insider	Sell	1,908	$59.76	$114,022.08	28,685
4/6/2022	Jeffrey W. Albers	CEO	Sell	5,000	$70.11	$350,550.00	183,243
3/17/2022	George Demetri	Director	Sell	10	$58.56	$585.60	5,812
3/16/2022	L. Becker Hewes	Insider	Sell	2,219	$60.00	$133,140.00
3/10/2022	Ariel Hurley	Insider	Sell	2,339	$57.15	$133,673.85
3/7/2022	Ariel Hurley	Insider	Sell	256	$56.19	$14,384.64
3/3/2022	Ariel Hurley	Insider	Sell	761	$60.27	$45,865.47
3/3/2022	Mark Alan Goldberg	Director	Buy	5,000	$59.98	$299,900.00
12/15/2021	L. Becker Hewes	Insider	Sell	729	$100.00	$72,900.00
12/13/2021	Kate Haviland	COO	Sell	1,000	$98.30	$98,300.00
12/7/2021	Tracey L. Mccain	EVP	Sell	5,000	$97.30	$486,500.00
11/15/2021	Jeffrey W. Albers	CEO	Sell	30,000	$114.50	$3,435,000.00
11/15/2021	L. Becker Hewes	Insider	Sell	729	$115.49	$84,192.21
11/3/2021	Tracey L. Mccain	EVP	Sell	5,000	$110.56	$552,800.00
10/15/2021	L. Becker Hewes	Insider	Sell	729	$102.66	$74,839.14
10/5/2021	Fouad Namouni	Insider	Sell	3,241	$98.18	$318,201.38
9/23/2021	Ariel Hurley	Insider	Sell	600	$110.00	$66,000.00
9/23/2021	Tracey L. Mccain	EVP	Sell	25,000	$108.85	$2,721,250.00

America dodged a crisis — next time it could be much worse

From Weiss Ratings | Ad

Legendary financial forecaster, Dr. Martin Weiss, has been warning us about it for months … He believes the next incident could lead to people seeing their bank accounts frozen.

Click here and follow the three simple steps Martin shares in this video to protect your savings whi

SEC Filings (Institutional Ownership Changes) for Blueprint Medicines (NASDAQ:BPMC)

Institutional Buying and Selling by Quarter

Blueprint Medicines Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
8/27/2024	Clearbridge Investments LLC	220,980	$23.82M	0.0%	N/A	0.353%
8/27/2024	Dana Investment Advisors Inc.	14,744	$1.59M	0.1%	+8.2%	0.024%
8/20/2024	Novo Holdings A S	175,000	$18.86M	0.9%	-51.2%	0.279%
8/16/2024	Creative Planning	12,351	$1.33M	0.0%	+27.1%	0.020%
8/16/2024	Algert Global LLC	65,540	$7.06M	0.2%	+81.0%	0.105%
8/16/2024	Driehaus Capital Management LLC	358,255	$38.61M	0.4%	+101.0%	0.572%
8/15/2024	Susquehanna Portfolio Strategies LLC	40,277	$4.34M	0.2%	-58.8%	0.064%
8/15/2024	Mackenzie Financial Corp	4,885	$0.53M	0.0%	+5.2%	0.008%
8/15/2024	The Manufacturers Life Insurance Company	168,759	$18.19M	0.0%	-8.4%	0.270%
8/15/2024	Millennium Management LLC	627,626	$67.65M	0.0%	+540.0%	1.002%
8/15/2024	AQR Capital Management LLC	78,103	$8.42M	0.0%	+30.2%	0.125%
8/15/2024	Alpha DNA Investment Management LLC	3,879	$0.42M	0.2%	N/A	0.006%
8/15/2024	Point72 Europe London LLP	13,569	$1.46M	0.1%	N/A	0.022%
8/15/2024	Point72 Hong Kong Ltd	3,339	$0.36M	0.0%	N/A	0.005%
8/14/2024	Fred Alger Management LLC	48,588	$5.24M	0.0%	+187.3%	0.078%
8/14/2024	Point72 Asset Management L.P.	501,581	$54.06M	0.1%	+79.3%	0.801%
8/14/2024	Marshall Wace LLP	351,756	$37.91M	0.1%	+52.7%	0.562%
8/14/2024	Xponance Inc.	4,174	$0.45M	0.0%	+8.2%	0.007%
8/14/2024	Bank of Montreal Can	69,040	$7.46M	0.0%	N/A	0.110%
8/14/2024	Integral Health Asset Management LLC	340,000	$36.65M	3.5%	+61.9%	0.543%
8/14/2024	Hood River Capital Management LLC	502,820	$54.19M	1.1%	+7.0%	0.803%
8/14/2024	Ally Bridge Group NY LLC	75,638	$8.15M	4.9%	-53.0%	0.121%
8/14/2024	1832 Asset Management L.P.	502,651	$54.18M	0.0%	+200,159.4%	0.803%
8/14/2024	ProShare Advisors LLC	12,012	$1.30M	0.0%	-21.1%	0.019%
8/14/2024	Profund Advisors LLC	18,114	$1.95M	0.1%	+10.6%	0.029%
8/13/2024	Ensign Peak Advisors Inc	306,316	$33.02M	0.1%	-4.1%	0.489%
8/13/2024	Sei Investments Co.	52,986	$5.71M	0.0%	+15.4%	0.085%
8/13/2024	Public Employees Retirement Association of Colorado	6,512	$0.70M	0.0%	-9.3%	0.010%
8/12/2024	XTX Topco Ltd	5,504	$0.59M	0.1%	N/A	0.009%
8/12/2024	Hsbc Holdings PLC	9,964	$1.06M	0.0%	N/A	0.016%
8/12/2024	Blair William & Co. IL	6,047	$0.65M	0.0%	-8.6%	0.010%
8/12/2024	Vanguard Personalized Indexing Management LLC	4,276	$0.46M	0.0%	+12.8%	0.007%
8/12/2024	Amalgamated Bank	2,154	$0.23M	0.0%	+5.3%	0.003%
8/12/2024	E Fund Management Co. Ltd.	5,768	$0.62M	0.0%	+22.9%	0.009%
8/10/2024	Mutual of America Capital Management LLC	32,446	$3.50M	0.0%	-4.1%	0.052%
8/9/2024	Edgestream Partners L.P.	10,323	$1.11M	0.1%	N/A	0.016%
8/9/2024	Renaissance Technologies LLC	110,400	$11.90M	0.0%	+132.4%	0.176%
8/9/2024	Citizens Financial Group Inc. RI	3,929	$0.42M	0.0%	N/A	0.006%
8/9/2024	Dimensional Fund Advisors LP	31,979	$3.45M	0.0%	-34.2%	0.051%
8/9/2024	Massachusetts Financial Services Co. MA	169,543	$18.27M	0.0%	N/A	0.271%
8/8/2024	Envestnet Asset Management Inc.	22,685	$2.45M	0.0%	-1.1%	0.036%
8/8/2024	William Blair Investment Management LLC	1,593,916	$171.79M	0.5%	-6.7%	2.546%
8/8/2024	O Neil Global Advisors Inc.	13,283	$1.43M	0.7%	N/A	0.021%
8/8/2024	Federated Hermes Inc.	62,354	$6.72M	0.0%	+27.8%	0.100%
8/8/2024	First Turn Management LLC	184,901	$19.93M	3.2%	N/A	0.295%
8/8/2024	Nicholas Investment Partners LP	40,611	$4.38M	0.5%	N/A	0.065%
8/8/2024	American Century Companies Inc.	802,733	$86.52M	0.1%	+4.2%	1.282%
8/8/2024	State of New Jersey Common Pension Fund D	24,202	$2.61M	0.0%	-32.4%	0.039%
8/6/2024	Emerald Advisers LLC	341,200	$36.78M	1.5%	-15.3%	0.545%
8/6/2024	Emerald Mutual Fund Advisers Trust	278,333	$30M	1.6%	-11.9%	0.444%
8/6/2024	Torray Investment Partners LLC	16,242	$1.75M	0.3%	-16.4%	0.026%
8/6/2024	Candriam S.C.A.	52,066	$5.61M	0.0%	+30.0%	0.083%
8/5/2024	Arizona State Retirement System	16,285	$1.76M	0.0%	+2.6%	0.026%
8/5/2024	Victory Capital Management Inc.	264,995	$28.56M	0.0%	+28.5%	0.423%
8/3/2024	TD Asset Management Inc	323,500	$34.87M	0.0%	-15.6%	0.517%
8/2/2024	Jackson Creek Investment Advisors LLC	10,186	$1.10M	0.4%	-34.1%	0.016%
8/1/2024	Rhumbline Advisers	91,543	$9.87M	0.0%	+6.0%	0.146%
8/1/2024	Gilbert & Cook Inc.	4,466	$0.48M	0.1%	-9.3%	0.007%
8/1/2024	Mraz Amerine & Associates Inc.	5,948	$0.64M	0.1%	-2.1%	0.009%
7/31/2024	nVerses Capital LLC	3,200	$0.35M	0.2%	+3,100.0%	0.005%
7/31/2024	Van ECK Associates Corp	1,116	$0.12M	0.0%	+13.3%	0.002%
7/29/2024	Crossmark Global Holdings Inc.	3,533	$0.38M	0.0%	N/A	0.006%
7/29/2024	Peregrine Capital Management LLC	79,560	$8.58M	0.3%	-15.0%	0.127%
7/29/2024	Principal Financial Group Inc.	58,191	$6.27M	0.0%	-7.1%	0.093%
7/29/2024	Panagora Asset Management Inc.	147,564	$15.90M	0.1%	-44.0%	0.236%
7/29/2024	Zurcher Kantonalbank Zurich Cantonalbank	13,792	$1.49M	0.0%	+8.4%	0.022%
7/26/2024	Legato Capital Management LLC	5,165	$0.56M	0.1%	N/A	0.008%
7/26/2024	Bank of New York Mellon Corp	273,930	$29.52M	0.0%	+13.6%	0.437%
7/26/2024	EFG Asset Management North America Corp.	27,884	$3.01M	0.5%	+0.5%	0.045%
7/25/2024	Calamos Advisors LLC	7,022	$0.76M	0.0%	-13.9%	0.011%
7/22/2024	Pallas Capital Advisors LLC	5,481	$0.62M	0.0%	+4.8%	0.009%
7/20/2024	China Universal Asset Management Co. Ltd.	7,355	$0.79M	0.1%	-37.5%	0.012%
7/19/2024	Raymond James & Associates	13,550	$1.46M	0.0%	+45.2%	0.022%
7/18/2024	Ellsworth Advisors LLC	5,173	$0.56M	0.2%	+6.8%	0.008%
7/18/2024	Triad Wealth Partners LLC	250	$27K	0.0%	N/A	0.000%
7/18/2024	Assenagon Asset Management S.A.	165,245	$17.81M	0.0%	-5.6%	0.264%
7/17/2024	Baader Bank Aktiengesellschaft	3,498	$0.37M	0.0%	+59.0%	0.006%
7/17/2024	Oak Ridge Investments LLC	15,744	$1.70M	0.2%	+29.2%	0.025%
7/16/2024	Diversified Trust Co	15,910	$1.72M	0.0%	+9.9%	0.025%
7/12/2024	SG Americas Securities LLC	21,684	$2.34M	0.0%	+82.8%	0.035%
7/11/2024	Clarus Wealth Advisors	2,384	$0.28M	0.1%	-3.8%	0.004%
7/10/2024	CWM LLC	1,105	$0.12M	0.0%	+114.6%	0.002%
7/9/2024	Harbor Capital Advisors Inc.	23,978	$2.58M	0.2%	-11.1%	0.038%
6/13/2024	NBW Capital LLC	50,944	$4.83M	1.0%	-3.4%	0.081%
6/4/2024	DekaBank Deutsche Girozentrale	25,883	$2.53M	0.0%	+2.9%	0.041%
5/28/2024	Teachers Retirement System of The State of Kentucky	13,358	$1.27M	0.0%	-12.7%	0.021%
5/17/2024	Comerica Bank	10,839	$1.03M	0.0%	+2,582.9%	0.018%
5/16/2024	California State Teachers Retirement System	58,071	$5.51M	0.0%	-5.4%	0.095%
5/16/2024	Jacobs Levy Equity Management Inc.	71,441	$6.78M	0.0%	N/A	0.117%
5/16/2024	Kennedy Capital Management LLC	2,320	$0.22M	0.0%	N/A	0.004%
5/16/2024	Redmile Group LLC	113,060	$10.73M	0.4%	N/A	0.185%
5/15/2024	Public Employees Retirement Association of Colorado	7,176	$0.68M	0.0%	-3.3%	0.012%
5/15/2024	Bellevue Group AG	5,100	$0.48M	0.0%	N/A	0.008%
5/15/2024	Price T Rowe Associates Inc. MD	6,250,823	$592.95M	0.1%	+15.1%	10.214%
5/15/2024	Hood River Capital Management LLC	470,126	$44.60M	1.0%	+6.8%	0.768%
5/15/2024	Lazard Asset Management LLC	2,658	$0.25M	0.0%	N/A	0.004%
5/14/2024	Natixis	768	$73K	0.0%	N/A	0.001%
5/14/2024	Pitcairn Co.	4,234	$0.40M	0.0%	-13.4%	0.007%
5/14/2024	CANADA LIFE ASSURANCE Co	6,834	$0.65M	0.0%	+3.9%	0.011%
5/14/2024	American International Group Inc.	29,971	$2.84M	0.0%	-0.9%	0.049%

Data available starting January 2016

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $84.10

$83.91

$86.65

50 Day Range

MA: $100.99

$84.10

$120.50

52 Week Range

Now: $84.10

$43.89

$121.90

Volume

470,107 shs

Average Volume

703,896 shs

Market Capitalization

$5.27 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.58

Who are the company insiders with the largest holdings of Blueprint Medicines?: Blueprint Medicines' top insider investors include:
Jeffrey W Albers (Director)
Kate Haviland (CEO)
Christina Rossi (COO)
Fouad Namouni (Insider)
Tracey L Mccain (EVP)
Michael Landsittel (CFO)
L Becker Hewes (Insider)
Debra Durso-Bumpus (Insider)
Percy H Carter (Insider)
Christopher K Murray (Insider)
Philina Lee (Insider)
Ariel Hurley (Insider)
Learn More about top insider investors at Blueprint Medicines.
Who are the major institutional investors of Blueprint Medicines?: Blueprint Medicines' top institutional investors include:
William Blair Investment Management LLC — 2.55%
American Century Companies Inc. — 1.28%
Millennium Management LLC — 1.00%
Hood River Capital Management LLC — 0.80%
1832 Asset Management L.P. — 0.80%
Point72 Asset Management L.P. — 0.80%
Learn More about top institutional investors of Blueprint Medicines stock.
Which major investors are selling Blueprint Medicines stock?: In the previous quarter, BPMC stock was sold by these institutional investors:
Novo Holdings A S
Panagora Asset Management Inc.
William Blair Investment Management LLC
Ally Bridge Group NY LLC
Emerald Advisers LLC
TD Asset Management Inc
Susquehanna Portfolio Strategies LLC
Emerald Mutual Fund Advisers Trust
Within the last year, company insiders that have sold Blueprint Medicines company stock include:
Jeffrey W Albers (Director)
Kate Haviland (CEO)
Christina Rossi (COO)
Fouad Namouni (Insider)
Tracey L Mccain (EVP)
Michael Landsittel (CFO)
L Becker Hewes (Insider)
Debra Durso-Bumpus (Insider)
Percy H Carter (Insider)
Christopher K Murray (Insider)
Philina Lee (Insider)
Ariel Hurley (Insider)
Learn More investors selling Blueprint Medicines stock.
Which major investors are buying Blueprint Medicines stock?: During the last quarter, BPMC stock was bought by institutional investors including:
Millennium Management LLC
1832 Asset Management L.P.
Point72 Asset Management L.P.
Clearbridge Investments LLC
First Turn Management LLC
Driehaus Capital Management LLC
Massachusetts Financial Services Co. MA
Integral Health Asset Management LLC